NCT01977534 - To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels | Biotech Hunter

Enrollment

1,005

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions

Coronary DiseaseCoronary Artery DiseaseCoronary Restenosis

Interventions

DEVICE

Absorb BVS

The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating \[formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating\].

Trial Locations (24)

Unknown

Lister Hospital, Stevenage

Basildon Hospital, Basildon

Royal Victoria Hospital, Belfast

Glan Clwyd District General Hospital, Bodelwyddan

Royal Bournmouth Hospital, Bournemouth

Sussex Cardiac Centre, Brighton

Bristol Heart Institute, Bristol

Papworth Hospital, Cambridge

Royal Infirmary of Edinburgh, Edinburgh

Frimley Park Hospital, Frimley

Golden Jubilee National Hospital, Glasgow

Leeds General Infirmary, Leeds

Glenfield Hospital, Leicester

Barts Heart Centre, London

Kings College Hospital, London

Northwick Park Hospital, London

Royal Brompton Hospital, London

Manchester Royal Infirmary, Manchester

James Cook University Hospital, Middlesbrough

The Freeman Hospital, Newcastle

Norfolk & Norwich University Hospital, Norwich

John Radcliffe Hospital, Oxford

Queen Alexandra Hospital, Portsmouth

Southampton General Hospital, Southampton